These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 13031855)

  • 1. [Experimental studies on fibrinolysis in normal and pathological conditions].
    MENGHINI G; CARNEVALI O; ORLANDI F
    Arch Sci Med (Torino); 1953 Jan; 95(1):1-8. PubMed ID: 13031855
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
    Gombás J; Tanka-Salamon A; Skopál J; Nagy Z; Machovich R; Kolev K
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):82-8. PubMed ID: 18180621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Index of fibrinolysis with new fibrin plate (author's transl)].
    Hishikawa Y; Sugie I
    Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [THE STRUCTURE OF FIBRIN FIBRILS DURING FIBRINOLYSIS].
    KUHNKE E; GILL IS
    Thromb Diath Haemorrh; 1963 Nov; 10():243-6. PubMed ID: 14081286
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular and cellular modulation of fibrinolysis.
    Kolev K; Machovich R
    Thromb Haemost; 2003 Apr; 89(4):610-21. PubMed ID: 12669114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease.
    Mörtberg J; Blombäck M; Wallén Å; He S; Jacobson SH; Spaak J
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):401-7. PubMed ID: 26650459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Fibrinolysis by Coagulation Factor XIII.
    Rijken DC; Uitte de Willige S
    Biomed Res Int; 2017; 2017():1209676. PubMed ID: 28761875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological fibrinolysis secondary to pseudoaneurysms.
    Babu SC; Bole P; Sharma P; Purdy R; Clauss RH
    Surgery; 1980 Feb; 87(2):202-4. PubMed ID: 7355390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a Radial Diffusion Method to Investigate the Role of Plasmin Degradation of Fibrin in a Physical Model of an Early-phase Wound.
    Chukwuemeka CP; Cupp J; Sanders JR
    Wounds; 2017 Apr; 29(4):115-121. PubMed ID: 28135202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [LYSOGRAPHY, A METHOD FOR DETERMINING FIBRINOLYSIS TIME].
    KUHNKE E; GILL IS
    Thromb Diath Haemorrh; 1963 Nov; 10():247-52. PubMed ID: 14081287
    [No Abstract]   [Full Text] [Related]  

  • 14. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basic concept for evaluating coagulation and fibrinolysis data].
    Hashiguchi T
    Rinsho Ketsueki; 2017; 58(10):2096-2103. PubMed ID: 28978854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activation of the fibrinolytic system in pulmonary excision; comparative study of fibrinolysis in normal conditions, in thoracic interventions and in extra-thoracic interventions].
    TONELLI L; SCALFATI P
    Ann Ital Chir; 1955; 32(10):865-94. PubMed ID: 13327727
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease.
    Adány R; Szegedi A; Ablin RJ; Muszbek L
    Thromb Haemost; 1988 Oct; 60(2):293-7. PubMed ID: 3064359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.
    ALKJAERSIG N; FLETCHER AP; SHERRY S
    J Clin Invest; 1962 Apr; 41(4):917-34. PubMed ID: 13860492
    [No Abstract]   [Full Text] [Related]  

  • 19. [Fatal pathological fibrinolysis during pregnancy interrupted by anti-Rh immunization].
    PIGEAUD ; REVOL L; FAVRE-GILLY J; BRUEL ; ITHIER
    Lyon Med; 1951 May; 184(20):333-8. PubMed ID: 14851844
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of cortisone and of prednisone on fibrinolysis (fibrin plate method). Experimental studies in guinea pigs].
    SOARDI F; SANTANGELO G
    Riv Ital Ig; 1959; 19():479-84. PubMed ID: 13832348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.